IP Library › Granted Patent US 10,369,193
Granted Patent B2
US 10,369,193 · App. 15/160,949 · Granted Aug 6, 2019

Gene therapy for neurodegenerative disorders

Inventors: Marco A. Passini (Northborough, MA); Lamya Shihabuddin (West Newton, MA); Seng H. Cheng (Natick, MA)
Assignee: Genzyme Corporation
A61K38/1709A61K31/7088A61K48/00A61K48/005A61K48/0008A61K48/0075C07K14/4702C12N7/00C12N15/86C12N2750/14121C12N2750/14133C12N2750/14143C12N2750/14171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,369,193
App. No.
15/160,949
Granted
Aug 6, 2019
Kind
B2
Abstract

Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.

Claims (13)

1. A recombinant adeno-associated virus (rAAV) virion for use in treating spinal muscular atrophy (SMA) in a subject comprising a self-complementary adeno-associated virus (scAAV) vector, wherein the scAAV vector comprises a polynucleotide encoding survival motor neuron (SMN), wherein the scAAV vector comprises AAV2 inverted terminal repeats (ITRs), and wherein the rAAV virion comprises an AAV8 capsid.

2. The rAAV virion of claim 1 , wherein the SMN protein is encoded by human SMN-1.

3. The rAAV virion of claim 2 , wherein the SMN protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2.

4. The rAAV virion of claim 3 , wherein the SMN protein comprises an amino acid sequence of SEQ ID NO:2.

5. A composition comprising a recombinant AAV virion according to claim 1 and a pharmaceutically acceptable excipient.

6. A method of treating SMA in a subject comprising administering a therapeutically effective amount of the composition of claim 5 to the subject.

7. A method of treating SMA in a subject in need thereof comprising administering the recombinant AAV virion according to claim 1 to the subject.

8. The method of claim 6 , wherein the composition is administered via administration into at least one region of the deep cerebellar nuclei of the cerebellum.

9. The method of claim 6 , wherein the composition is administered via direct spinal cord injection.

10. The method of claim 6 , wherein the composition is administered via intracerebroventricular injection.

11. The method of claim 10 , wherein the composition is administered into at least one cerebral lateral ventricle.

12. The method of claim 6 , wherein the composition is administered via both intracerebroventricular injection and direct spinal cord injection.

13. The method of claim 6 , wherein the composition is administered via intrathecal injection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: PASSINI, MARCO; SHIHABUDDIN, LAMYA; CHENG, SENG
To: GENZYME CORPORATION
Reel/Frame 038967/0286 →
Continuity (5)
Continuation 13287583 · Nov 2, 2011
Continuation PCTUS2010001239 · Apr 27, 2010
Provisional Application 61174982 · May 2, 2009
Provisional Application 61268059 · Jun 8, 2009
Related Publication 20170087212A1 · Mar 30, 2017
Cited By (3)
US 12,350,311 US 12,611,436 US 12,656,353